Cargando…
Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02)
To evaluate the efficacy and toxicity of the sequential nonplatinum combination chemotherapy consisting of gemcitabine (GEM) and vinorelbine (VNR) followed by docetaxel (DOC) in patients with advanced non-small-cell lung cancer (NSCLC), we conducted the multiinstitutional phase II study. A total of...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747544/ https://www.ncbi.nlm.nih.gov/pubmed/12569374 http://dx.doi.org/10.1038/sj.bjc.6600723 |
_version_ | 1782172105020801024 |
---|---|
author | Hosoe, S Komuta, K Shibata, K Harada, H Iwamoto, Y Ohsaki, Y Morioka, T Origasa, H Fukushima, M Furuse, K Kawahara, M |
author_facet | Hosoe, S Komuta, K Shibata, K Harada, H Iwamoto, Y Ohsaki, Y Morioka, T Origasa, H Fukushima, M Furuse, K Kawahara, M |
author_sort | Hosoe, S |
collection | PubMed |
description | To evaluate the efficacy and toxicity of the sequential nonplatinum combination chemotherapy consisting of gemcitabine (GEM) and vinorelbine (VNR) followed by docetaxel (DOC) in patients with advanced non-small-cell lung cancer (NSCLC), we conducted the multiinstitutional phase II study. A total of 44 chemotherapy-naive patients with advanced NSCLC were treated with GEM 1000 mg m(−2) and VNR 25 mg m(−2) intravenously on days 1 and 8 every 3 weeks for three cycles. DOC 60 mg m(−2) was then administrated intravenously at 3-week intervals for three cycles. Patients were evaluated for response and toxicity with each cycle of the treatment. The major objective response rate was 47.7% (95% confidence interval (CI), 33.8–62.1%). Median survival time (MST) was 15.7 months and 1-year survival rate was 59%. In the GEM/VNR cycle, grade 3/4 neutropenia occurred in 36.3%, grade 3/4 anaemia in two patients (4.5%) and grade 3 thrombocytopenia in one patient (2.3%). Grade 3 pneumonitis occurred in two patients (4.5%) in GEM/VNR cycles. In the DOC cycles, grade 3/4 neutropenia occurred in 39.4% but no patient experienced grade 3/4 anaemia or thrombocytopenia. Of the 44 eligible patients, 33 patients completed three cycles of GEM/VNR and 22 patients completed six cycles of planned chemotherapy (three cycles of GEM/VNR followed by three cycles of DOC). The sequential triplet nonplatinum chemotherapy consisted of GEM/VNR followed by DOC, and was very active and well tolerated. This study forms the basis for an ongoing phase III trial that compares this nonplatinum triplet and standard platinum doublet combination (carboplatin/paclitaxel). |
format | Text |
id | pubmed-2747544 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-27475442009-09-21 Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02) Hosoe, S Komuta, K Shibata, K Harada, H Iwamoto, Y Ohsaki, Y Morioka, T Origasa, H Fukushima, M Furuse, K Kawahara, M Br J Cancer Clinical To evaluate the efficacy and toxicity of the sequential nonplatinum combination chemotherapy consisting of gemcitabine (GEM) and vinorelbine (VNR) followed by docetaxel (DOC) in patients with advanced non-small-cell lung cancer (NSCLC), we conducted the multiinstitutional phase II study. A total of 44 chemotherapy-naive patients with advanced NSCLC were treated with GEM 1000 mg m(−2) and VNR 25 mg m(−2) intravenously on days 1 and 8 every 3 weeks for three cycles. DOC 60 mg m(−2) was then administrated intravenously at 3-week intervals for three cycles. Patients were evaluated for response and toxicity with each cycle of the treatment. The major objective response rate was 47.7% (95% confidence interval (CI), 33.8–62.1%). Median survival time (MST) was 15.7 months and 1-year survival rate was 59%. In the GEM/VNR cycle, grade 3/4 neutropenia occurred in 36.3%, grade 3/4 anaemia in two patients (4.5%) and grade 3 thrombocytopenia in one patient (2.3%). Grade 3 pneumonitis occurred in two patients (4.5%) in GEM/VNR cycles. In the DOC cycles, grade 3/4 neutropenia occurred in 39.4% but no patient experienced grade 3/4 anaemia or thrombocytopenia. Of the 44 eligible patients, 33 patients completed three cycles of GEM/VNR and 22 patients completed six cycles of planned chemotherapy (three cycles of GEM/VNR followed by three cycles of DOC). The sequential triplet nonplatinum chemotherapy consisted of GEM/VNR followed by DOC, and was very active and well tolerated. This study forms the basis for an ongoing phase III trial that compares this nonplatinum triplet and standard platinum doublet combination (carboplatin/paclitaxel). Nature Publishing Group 2003-02-10 2003-02-10 /pmc/articles/PMC2747544/ /pubmed/12569374 http://dx.doi.org/10.1038/sj.bjc.6600723 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Hosoe, S Komuta, K Shibata, K Harada, H Iwamoto, Y Ohsaki, Y Morioka, T Origasa, H Fukushima, M Furuse, K Kawahara, M Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02) |
title | Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02) |
title_full | Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02) |
title_fullStr | Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02) |
title_full_unstemmed | Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02) |
title_short | Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02) |
title_sort | gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase ii trial of nonplatinum sequential triplet combination chemotherapy (jmto lc00-02) |
topic | Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747544/ https://www.ncbi.nlm.nih.gov/pubmed/12569374 http://dx.doi.org/10.1038/sj.bjc.6600723 |
work_keys_str_mv | AT hosoes gemcitabineandvinorelbinefollowedbydocetaxelinpatientswithadvancednonsmallcelllungcanceramultiinstitutionalphaseiitrialofnonplatinumsequentialtripletcombinationchemotherapyjmtolc0002 AT komutak gemcitabineandvinorelbinefollowedbydocetaxelinpatientswithadvancednonsmallcelllungcanceramultiinstitutionalphaseiitrialofnonplatinumsequentialtripletcombinationchemotherapyjmtolc0002 AT shibatak gemcitabineandvinorelbinefollowedbydocetaxelinpatientswithadvancednonsmallcelllungcanceramultiinstitutionalphaseiitrialofnonplatinumsequentialtripletcombinationchemotherapyjmtolc0002 AT haradah gemcitabineandvinorelbinefollowedbydocetaxelinpatientswithadvancednonsmallcelllungcanceramultiinstitutionalphaseiitrialofnonplatinumsequentialtripletcombinationchemotherapyjmtolc0002 AT iwamotoy gemcitabineandvinorelbinefollowedbydocetaxelinpatientswithadvancednonsmallcelllungcanceramultiinstitutionalphaseiitrialofnonplatinumsequentialtripletcombinationchemotherapyjmtolc0002 AT ohsakiy gemcitabineandvinorelbinefollowedbydocetaxelinpatientswithadvancednonsmallcelllungcanceramultiinstitutionalphaseiitrialofnonplatinumsequentialtripletcombinationchemotherapyjmtolc0002 AT moriokat gemcitabineandvinorelbinefollowedbydocetaxelinpatientswithadvancednonsmallcelllungcanceramultiinstitutionalphaseiitrialofnonplatinumsequentialtripletcombinationchemotherapyjmtolc0002 AT origasah gemcitabineandvinorelbinefollowedbydocetaxelinpatientswithadvancednonsmallcelllungcanceramultiinstitutionalphaseiitrialofnonplatinumsequentialtripletcombinationchemotherapyjmtolc0002 AT fukushimam gemcitabineandvinorelbinefollowedbydocetaxelinpatientswithadvancednonsmallcelllungcanceramultiinstitutionalphaseiitrialofnonplatinumsequentialtripletcombinationchemotherapyjmtolc0002 AT furusek gemcitabineandvinorelbinefollowedbydocetaxelinpatientswithadvancednonsmallcelllungcanceramultiinstitutionalphaseiitrialofnonplatinumsequentialtripletcombinationchemotherapyjmtolc0002 AT kawaharam gemcitabineandvinorelbinefollowedbydocetaxelinpatientswithadvancednonsmallcelllungcanceramultiinstitutionalphaseiitrialofnonplatinumsequentialtripletcombinationchemotherapyjmtolc0002 |